[Effects of yiqi huoxue compound contained drug serum on the expressions of toll-like receptor 4 and downstream signal transduction pathway, and LOX-1, TNF-alpha, ICAM-1 in the human vein endothelial cells].
To investigate the effects of Yiqi Huoxue Compound (YHC) contained drug serum on the expressions of TLR4 and its downstream signal transduction pathway and LOX-1, TNF-alpha, ICAM-1 in human umbilical vein endothelial cells (HUVECs), and to study its possible anti-atherosclerosis (AS) mechanism. METHODS Twenty New Zealand rabbits were divided into 4 groups in random, i. e., the normal control group, the high concentration group, the middle concentration group, and the low concentration group, 5 in each group. Normal saline was given to rabbits in the normal control group by gastrogavage. High, middle, and low concentration of YHC was respectively given to rabbits in the rest 3 groups by gastrogavage for 7 successive days. The blood was withdrawn from the heart 2 h after the last gastrogavage. The serum was isolated after centrifuge. HUVECs was in vitro cultured and then randomly divided into 6 groups, i. e., the normal control group, the model group, the Western medicine control group, the high, middle, and low YHC groups. HUVECs were stimulated with LPS for 2 h, and then treated with high, middle, and low YHC contained serum. HUVECs were collected 24 h later. The gene expressions of TLR4, MyD88, TRAF-6, TRAM, TRIF, NF-kappaB, LOX-1, TNF-alpha, and ICAM-1 were detected using fluorescent quantitative PCR. The protein expressions of TLR4, MyD88, TRAF-6, and LOX-1 were determined using Western blot method. After HUVECs were stimulated by LPS, the expressions of TLR4, MyD88, TRAF-6, TRAM, TRIF, NF-kappaB, LOX-1, TNF-alpha, and ICAM-1 were enhanced, showing statistical difference when compared with the vehicle control group (P < 0.01). YHC contained serum significantly decreased the higher expressions of TLR4, MyD88, TRAF-6, NF-kappaB, LOX-1, TNF-alpha, and ICAM-1, showing statistical difference when compared with the model group (P < 0.05). YHC could inhibit the TLR signal transduction pathway and the expressions of LOX-1, TNF-alpha, and ICAM-1. These might be one of the mechanisms for treating various immune inflammatory diseases and preventing AS.